Navigation Links
Teewinot Life Sciences Corporation Announces Breakthrough Commercial Production of the Cannabinoid Varin Series
Date:2/14/2017

TAMPA, Fla., Feb. 14, 2017 /PRNewswire/ -- Teewinot Life Sciences Corporation (Teewinot), a global leader in the use of biosynthetic processes for the production of kilogram quantities of pharmaceutical grade cannabinoids, announced today that its wholly owned subsidiary, Full Spectrum Laboratories, Ltd. (FSL), can produce commercial quantities of THCVA, CBDVA, CBCVA, and CBGVA (varin series) using its proprietary CannSynthesis™ technology.  Teewinot and FSL are recognized as pioneers in synthesizing pharmaceutically important cannabinoids.  It is not practical to commercially produce the varin series compounds by means of plant extraction because the Cannabis plant only produces small quantities of these cannabinoids.  FSL has developed patent-protected biosynthetic processes for the manufacture of THCVA, CBDVA, CBCDA, and CBGVA using enzymes such as THCA synthase and CBDA synthase.

Dr. Richard Peet, Executive Vice President of Teewinot and co-inventor of the CannSynthesis™ technology stated, "Our proprietary CannSynthesis™ process makes possible the cost-effective production of commercial quantities of pharmaceutically pure cannabinoids that are produced in relatively small quantities by the Cannabis plant.  Using FSL's revolutionary biosynthetic process, it is now possible to envision treating patients with cannabinoids that are impractical to cost-effectively produce in commercial quantities by plant extraction or chemical synthesis."

Jeffrey M. Korentur, Teewinot President and CEO says, "It's hard to overstate the significance that this expansion of our manufacturing catalog provides.  Researchers around the world are demanding better access to this important, and demonstrably effective sub-set of cannabinoids, and Teewinot is excited to be the market leader in this space.  Until now, there has been no commercially reliable method of producing these molecules.  The CannSynthesis™ process ensures global availability of the varin series at a reasonable cost, and with a supply chain that can effortlessly scale to meet the demands of the market.  CannSynthesis™ eliminates the risks associated with agricultural and chemical production methods, yet provides the purest cannabinoids to the research, medical and pharmaceutical communities."

Teewinot is the global leader for commercial production of pharmaceutically pure (>99%) THCA, CBDA, CBCA, CBGA, THCVA, CBDVA, CBCVA, and CBGVA.  Teewinot seeks partners interested in working to commercialize these important cannabinoids and provide patients with new healthcare solutions.

About Teewinot Life Sciences Corporation

Teewinot Life Sciences Corporation is an international biopharmaceutical company focused on advanced pharmaceutical research and the use of novel biosynthetic processes such as biocatalysis and synthetic biology for cannabinoid manufacture.  Coupled with patented formulation technologies, Teewinot is a leader in the production and delivery of cannabinoid-based therapies.  With headquarters in Tampa, Florida, and wholly owned subsidiaries Full Spectrum Laboratories, Ltd, in Ireland, and Canadian Medical Hemp Biotechnologies in Canada, Teewinot's global proprietary technology and intellectual property portfolio represent a breakthrough in the manufacture and delivery of cannabinoid-based pharmaceuticals.  For more information, please visit www.tlscorp.com or follow us on Twitter (@teewinot_corp).

For More Information:

Teewinot Life Sciences Corporation
Drew White
drew@nisonco.com
(631) 520-1435

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/teewinot-life-sciences-corporation-announces-breakthrough-commercial-production-of-the-cannabinoid-varin-series-300406556.html


'/>"/>
SOURCE Teewinot Life Sciences Corporation
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. Teewinot Life Sciences Corporation Licenses Biosynthetic Technology to AMRI for the Production and Sale of the First Commercially Available CBCA Analytical Standard
2. CSO of Vortex Biosciences Dr. Elodie Sollier-Christen Awarded With 2017 SLAS Innovation Award
3. Swift Biosciences Expands Team, Hires Vice President of Marketing
4. Life Sciences Forum Executives Announced
5. Knowledgent Clinical Cloud Built on Amazon Web Services Transforms Clinical Informatics in Life Sciences
6. Exact Sciences to participate in Leerink Partners Global Healthcare Conference
7. ACEA Biosciences Announces Winners of its Travel Award
8. NSF International’s Bob Pietrowski to Retire as Vice President of Global Health Sciences Division
9. Student-Run DuPont Plant Sciences Symposium Series Kicks Off at University of Missouri
10. AxioMed Continues International Growth with Workshop and Presentation at Caribbean Neurosciences Symposium in Montego Bay
11. WuXi AppTec Acquires Biology Focused R&D Service Leader HD Biosciences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... A new study published in Fertility ... fresh in vitro fertilization (IVF) transfer cycles. The multi-center matched cohort ... After comparing the results from the fresh and frozen transfer cohorts, the authors ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... antibody-drug conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive ... a technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). ...
(Date:10/10/2017)... research firm Parks Associates announced today that Tom Kerber ... Annual Meeting , October 11 in Scottsdale, Arizona . ... how smart safety and security products impact the competitive landscape. ... Parks Associates: Smart Home Devices: Main Purchase Driver ... "The residential security market has experienced continued growth, and the ...
(Date:10/10/2017)... PITTSBURGH, PA (PRWEB) , ... October 10, 2017 ... ... this year’s recipients of 13 prestigious awards honoring scientists who ... be presented in a scheduled symposium during Pittcon 2018, the world’s leading conference ...
Breaking Biology Technology:
(Date:4/11/2017)... 11, 2017 NXT-ID, Inc. (NASDAQ:   ... announces the appointment of independent Directors Mr. Robin D. ... Board of Directors, furthering the company,s corporate governance and expertise. ... Gino Pereira , ... forward to their guidance and benefiting from their considerable expertise ...
(Date:4/5/2017)... Today HYPR Corp. , leading innovator ... of the HYPR platform is officially FIDO® Certified ... architecture that empowers biometric authentication across Fortune 500 enterprises ... over 15 million users across the financial services industry, ... product suites and physical access represent a growing portion ...
(Date:4/3/2017)... , April 3, 2017  Data ... precision engineering platform, detected a statistically significant ... product prior to treatment and objective response ... the potential to predict whether cancer patients ... to treatment, as well as to improve ...
Breaking Biology News(10 mins):